Rejuvel Bio-Sciences EBIT

The latest EBIT for NUUU is $-810K as of September 2015. That compares with $-620K in the prior-year period — down 30.9% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Rejuvel Bio-Sciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, NUUU's EBIT moved from $-620K to $-810K — a 30.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Rejuvel Bio-Sciences's operating scale or balance-sheet position.

Against its sector companies, NUUU currently prints $-810K for EBIT, while the sector average sits near $2.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Rejuvel Bio-Sciences's growth, margins, and balance sheet.

A EBIT figure of $-810K for NUUU is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting NUUU's EBIT ($-810K), review year-over-year change from $-620K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.